Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | CDC25B | P30305 | 4/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10408203 | 0.88 | PDE4D (0.51) | TACR2PDPK1MTORPDE4DSLC6A2 | |
| SCHEMBL10408205 | 0.88 | PDE4D (0.51) | TACR2PDPK1MTORPDE4DSLC6A2 | |
| SCHEMBL15968116 | 0.87 | NT5E (0.54) | TACR2PDPK1MTORPTPN1CDC25B | |
| SCHEMBL17766609 | 0.87 | NT5E (0.54) | TACR2PDPK1MTORPTPN1CDC25B | |
| SCHEMBL3898371 | 0.87 | NT5E (0.54) | TACR2PDPK1MTORPTPN1CDC25B | |
| SCHEMBL3898367 | 0.87 | NT5E (0.54) | TACR2PDPK1MTORPTPN1CDC25B | |
| SCHEMBL25084155 | 0.86 | PTPN1 (0.49) | PDPK1MTORPTPN1CDC25BNT5E | |
| SCHEMBL9124670 | 0.86 | PDPK1 (0.47) | TACR2PDPK1MTORSLC6A2PTPN1 | |
| SCHEMBL6303407 | 0.83 | TSHR (0.49) | TACR2PTPN1CDC25BNT5ETSHR | |
| SCHEMBL8723384 | 0.82 | HTR1A (0.52) | TACR2PDE4DSLC6A2PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878690-B2 | Compounds and methods | PHARMAXIS PTY LTD. (AU) | 2005-04-12 | — | — | US | disclosed |
| EP-1301522-A4 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2004-04-14 | — | — | EP | disclosed |
| US-20030176363-A1 | Novel compounds and methods | PHARMAXIS PTY LTD. (AU) | 2003-09-18 | — | — | US | disclosed |
| EP-1301522-A1 | NOVEL COMPOUNDS AND METHODS | Pharmaxis Pty Ltd (AU) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004472-A1 | NOVEL COMPOUNDS AND METHODS | PHARMAXIS PTY LTD (AU) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176363-A1 | Novel compounds and methods | NFATC1, CD4, CCR5 | TACR2 4371/4885PDPK1 478/4885MTOR 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.